Eversense from Senseonics: The First Implantable CGM
For the first time in the United States, an implantable continuous glucose monitor (CGM) has been cleared by the U.S. Food and Drug Administration (FDA) for users over the age of 18. Could implantable technology be the future of continuous glucose monitoring? Meet the Eversense CGM, made by device company Senseonics.
The Eversense CGM consists of three main parts—the long-lasting sensor, the smart transmitter and the mobile app. The most groundbreaking part of this technology is the long-lasting sensor, which is implanted subcutaneously (under the skin) in the upper arm by a physician. This sensor uses a patented fluorescent technology to measure blood glucose levels. Then, the information gathered by the sensor is relayed to the smart transmitter, which sits on the skin over the implanted sensor. This value is sent via Bluetooth to the mobile app.
When the implant needs to be replaced, it must be done so by a qualified physician. However, Senseonics is already working on getting their Eversense XL approved by the FDA, which will last six months. Both versions of the CGM have already been on the market overseas for around two years.
For now, the FDA has only cleared the Eversense CGM for adjunctive use, meaning it has to be used in addition to fingerstick monitoring.
For more information on the The Eversense CGM, review the PRECISE II study, which included 90 patients living with diabetes.
Features to Consider
- Capable of providing 90-day continuous wear with no interruptions in readings.
- Remove the transmitter without removing the sensor—flexible and quick on-off.
- Transmitter provides on-body vibration alarms even if your phone is out of range.
- Highly accurate new CGM option—studies have shown Eversense to be as accurate or more accurate than currently commercially available continuous-wear sensors.
- Requires doctors appointments and procedures every 90 days and additional associated costs.
Read more about Continuous Glucose Monitors here.
